

Stabilizing the return to normal behavior in an epidemic

Tyrus Berry^{a,1}, Matthew Ferrari^{b,1,2}, Timothy Sauer^a, Steven J. Greybush^c, Donald Ebeigbe^d, Andrew J. Whalen^{e,f}, and Steven J. Schiff^f

This manuscript was compiled on October 20, 2023

Predicting the interplay between infectious disease and behavior has been an intractable problem because behavioral response is so varied. We introduce a general framework for feedback between incidence and behavior for an infectious disease. By identifying stable equilibria, we provide policy end-states that are self-managing and self-maintaining. We prove mathematically the existence of two new endemic equilibria depending on the vaccination rate: one in the presence of low vaccination but with reduced societal activity (the “new normal”), and one with return to normal activity but with vaccination rate below that required for disease elimination. This framework allows us to anticipate the long-term consequence of an emerging disease and design a vaccination response that optimizes public health and limits societal consequences.

Epidemic | Endemic | Behavior | Stability | Equilibria

To understand and control epidemics, models have been developed that reflect the fundamental properties of infectious disease transmission (1). To embody biological understanding and develop effective policy these models rely on abstractions of complicated phenomena: mortality, reinfection, vaccination, loss of immunity and spatial networks (2). Nevertheless, a substantial barrier to progress has been that transmission depends on human behavior, which is impossible to model in detail. To meet this challenge, we must consider all possible responses with minimal assumptions about the behavioral response to disease.

A hallmark of classical models for emergent epidemic dynamics is a large initial outbreak with final size larger than the critical herd immunity threshold (3). The initial emergent epidemic is followed by a period of low prevalence and then outbreaks of much smaller magnitude. This phenomenon raised concerns about the magnitude of the initial waves of infection of Ebola in 2014 (4), SARS-CoV-2 in 2020 (5, 6), and Mpox in 2022 (7, 8), and the potential strain on health systems from such large initial epidemic waves in the absence of behavioral restrictions. However, in all three settings, the initial epidemic wave was curtailed by behavioral change that resulted from a combination of individual behavior to limit risk of exposure and top-down restrictions.

For example, as shown in Fig. 1, in the first year of the SARS-CoV-2 pandemic, before the emergence of the first meaningful immune-escape variant (Alpha in November 2020), many local regions saw a second wave of the original wild-type virus that was equal to, or larger than, the magnitude of the initial emergent epidemic. This implies that behavioral changes, whether individual behavioral or legislated closures, may have limited the size of the first wave, which left a sufficiently large susceptible population that a second wave began when behavior and contact patterns returned towards pre-SARS-CoV-2 levels. The collective experience of these recent global emergence events suggests that disease modeling frameworks that do not account for behavioral change are insufficient to predict the dynamics of the emergence of pathogens exhibiting sufficient morbidity and mortality that will drive behavioral change.

Behavioral modeling can take many forms depending on whether the behavior patterns of interest are exogenous or endogenous to the disease. Exogenous effects on spread of disease include seasonality or long-established societal patterns of behavior. These are distinguished by a lack of dependence on the state of the disease (number of susceptible, infected, or recovered people) and can be modeled as external covariates; e.g. transmission rate as a function of relative humidity (9) or contact rates as a function of time of year (10). In contrast, endogenous effects (i.e. feedbacks) are dependent on the state of the system (e.g. incidence), including individual choices to modify behavior or policy changes that influence

Significance Statement

The experience of the COVID-19 pandemic has revealed that behavior can change dramatically in response to the spread of a disease. This behavioral response impacts disease transmission. Predicting future outcomes requires accounting for the feedback between behavior and transmission. We show that accounting for these feedbacks generates long-term predictions about disease burden and behavior that can guide policy.

Author affiliations: ^aDepartment of Mathematical Sciences, George Mason University, Fairfax, VA, USA; ^bDepartment of Biology, Center for Infectious Disease Dynamics, Penn State University, University Park, PA, USA; ^cDepartment of Meteorology and Atmospheric Science and Institute for Computational and Data Sciences, Penn State University, University Park, PA, USA; ^dDepartment of Electrical Engineering, Penn State University, University Park, PA, USA; ^eDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; ^fDepartment of Neurosurgery, Yale University, New Haven, CT, USA

¹A.O.(Author One) contributed equally to this work with A.T. (Author Two).

²To whom correspondence should be addressed. E-mail: mj1283@psu.edu

behavior in response to incidence or mortality. Traditional compartmental models omit such feedbacks and are unable to reproduce the breadth of phenomena illustrated in Fig. 1.

Exogenous variables have been used retrospectively to account for observed behavioral phenomena coincident with epidemic dynamics. For example, modern technology such as cell phone based mobility data has enabled exogenous modeling of behavior (11–13). Modeling behavior as a function of exogenous variables permits only retrospective evaluation of the interaction between behavior and transmission. Policy decisions need to anticipate future changes in behavior and thus require a framework that can account for future behavioral change.

In this article we show that the addition of a population level behavioral feedback (between incidence and transmission rate) to the classical SIR model, under a surprisingly weak set of assumptions, implies the existence of three possible equilibrium states: (1) for high vaccination rates, disease eradication, (2) for a medium range of vaccination, an endemic equilibrium with return to normal activity, (3) for low vaccination rates, a “new normal” equilibrium with reduced societal activity. We will also show that the SIR model with activity term can have a wider range of stereotypical behavior, which includes qualitative dynamics during emergence consistent with those shown in Fig. 1.

We show how a wide range of possible endogenous behavioral responses (e.g. distancing, masking, hygiene) can be introduced in a compartmental modeling framework (eg. susceptible, infectious, and recovered, or SIR (14)) in a completely general way. Rather than specify a particular model of behavioral response, we choose reasonable and intuitive properties as assumptions to constrain the form of the behavioral response.




Fig. 1. SARS-CoV-2 deaths exhibited multiple increasing waves in some US states prior to documented immune escape. Left: SARS-CoV-2 deaths for 54 US states and territories over the period from Feb. 1, 2020 to Oct. 1, 2020 smoothed with a 56-day moving average and normalized by the peak deaths. Note the large gap in peaks between June and July; the traces cluster into two groups: Peak before June (yellow) and peak after July (purple). Right: Aggregating these two clusters (solid line is the cluster mean and shaded area shows one standard deviation), we see that the yellow cluster exhibits a large initial peak with either no second wave or a smaller second wave (during this time period), whereas the purple cluster exhibits two increasing waves. The dynamic exhibited by the purple cluster cannot be captured by a simple compartmental model and is difficult to explain with spatial dynamics, motivating us to introduce a framework for modeling behavior as a possible explanation. Analysis based on the JHU CSSE COVID-19 Data (15) available at <https://github.com/CSSEGISandData/COVID-19>.

There has been significant work analyzing models with feedback between incidence and vaccination behavior (willingness or hesitancy) (16, 17). Bauch and Earn (16) showed the existence of stable equilibrium vaccination demand that can explain the challenge of attaining universal coverage. There has comparatively little work modeling feedback between

incidence and activity (18, 19) as applied to behavioral interventions to limit transmission. Current methods typically rely on choosing a particular model for the feedback (20–27). The key advance here is that we avoid the problematic issue of model specification, so the conclusions we reach are widely applicable, including novel emergence scenarios in unknown behavioral contexts.

Consider a standard disease modeling framework (1, 14) for a single well-mixed population that includes vaccination and loss of immunity. We reflect the endogenous/exogenous dichotomy by decomposing the transmission rate, β , into a product of exogenous and endogenous components. The endogenous response is represented with a single variable, a , (the instantaneous *activity* of individuals averaged over the population) that quantifies the instantaneous rate of effective behavioral interactions. Rather than specify an exact model for the activity dynamics, we assume that the rate of change of activity is determined by an unspecified *reactivity function*. Without specifying the reactivity function, we base our results on the following three assumptions:

- A1. Reactivity:** Change of activity depends on the current level of activity and incidence of infection.
- A2. Resilience:** When incidence of infection is zero, activity will return to a baseline level.
- A3. Boundedness:** Activity does not exceed the baseline level.

Reactivity reflects the assumption that the population chooses its aggregate activity level based on information available; specifically the currently observed activity level and knowledge of disease incidence. This means that the reactivity function, F , is a function of activity, a , and disease incidence, c , or $F(a, c)$, and does not depend on other variables. Thus, reactivity does not reflect exogenous influences.

We define a *baseline* activity level as the level of activity that the population would go to if the disease were removed and the activity was allowed to stabilize.

Resilience is here defined as the ability of the activity to spring back to the previous condition when distorting forces are removed. In this case, new infections are a distorting force, so *resilience* is the assumption that when disease incidence is zero the activity averaged over the population will return towards the baseline level. We also assume that, when there is no incidence, the baseline activity level is stationary.

Boundedness asserts that the baseline activity level of the population that exists in the absence of infection is also the maximum activity level. We assign this maximum level to be 1 in arbitrary units, so that the activity level a is always between 0 and 1.

Using only these assumptions, we show that the disease equilibria and stability are determined almost entirely by the vaccination rate, v , regardless of the behavioral model. We illustrate that accounting for an endogenous behavioral feedback gives rise to a novel equilibrium en route to the classical vaccine-based elimination threshold. The existence of this novel equilibrium can be used as a way-point to guide policy to achieve a return to normal behavior coincident with disease control.

1. Results

Starting from the *reactivity* assumption (A1), we first developed a framework for incorporating any reactive behavioral dynamics into the compartmental disease modeling paradigm (see Methods). The state of the modeled disease at any given time can be characterized by three variables (Fig 2): the percentage of the population that is susceptible, s , the percentage infected, i , and the activity relative to the baseline, a . The novelty here is that the reactivity function, F , which determines the feedback between activity and infection rate, is left completely unspecified. This means our results will apply very broadly to any behavioral response that satisfies our basic assumptions.




Fig. 2. Universal equilibria of resilient behavioral responses with high (left) and low (right) vaccination. The state space (gray shading) of the SIR model with endogenous behavioral feedback plotted on the susceptible (s), infected (i), and activity (a , where $a = 1$ represents the baseline activity level) axes. The susceptible and infected population sizes are instantaneously constant along the purple and yellow surfaces, respectively. An equilibrium must occur along the blue line that shows the intersection of the purple surface with the front of the domain (the $i = 0$ plane) or along the red curve that shows the intersection of these surfaces. When vaccine rates, v , are greater than the critical threshold, T_1 (see left panel), the only equilibrium is disease-free (blue) and resilience will drive the activity to baseline which is the top of the blue line. When vaccination rates drop below the T_1 (right panel), the baseline endemic equilibrium (green dot) is created, along with at least one new normal endemic equilibrium which can be anywhere along the red curve.

First, for any model with reactivity (Assumption A1), we find a universal vaccination threshold, T_1 , that is independent of the feedback between activity and incidence. When the vaccination rate is above this threshold any equilibrium must be disease-free. Fig. 2 illustrates the surfaces where the infected population (yellow) and the susceptible population (purple) are not changing; an equilibrium can only happen at the intersection of these two surfaces, or where the purple surface intersects the $i = 0$ plane (disease-free). When the vaccination rate is greater than T_1 the only equilibrium is disease-free (Fig. 2a, and Supporting Information figure Fig. S.1a).

Second, by assuming resilience (Assumption A2), we prove that when the vaccination rate is above T_1 the disease-free equilibrium is stable in the face of baseline activity (Fig. S.1a). Resilience assumes that when incidence is zero (disease-free) and activity is below baseline, then activity will increase. While this seems intuitive it does not imply stability by itself. Stability requires that even if we perturb the disease-free equilibrium by introducing a small number of infections, the system must return to the disease-free equilibrium. In Theorem 3 (Supporting Information), we prove that the disease-free equilibrium is in fact stable, as long as the vaccination rate is above T_1 .

Assuming both reactivity (A1) and resilience (A2), when the vaccination rate drops below the universal threshold T_1 ,

the disease-free equilibrium becomes unstable, and endemic equilibria become possible (Fig. 2b). One novel equilibrium, which we call the *baseline endemic equilibrium*, is stable even when activity is at baseline ($a = 1$). For a baseline endemic equilibrium to exist, we only require that normal activity be stationary for this incidence level, meaning that $F(1, c) = 0$. Not every reactivity function, F , will have a baseline endemic equilibrium, and we give several examples in Section 2 of reactivity functions that show the range of possibilities. If the baseline endemic equilibrium does exist, the infection rate at equilibrium depends on the vaccination rate, but is independent of the behavioral model.

While not as desirable as a disease-free equilibrium, an endemic equilibrium with baseline activity ($a = 1$) may still be preferred to permanently modifying behavior, so it is important to determine its stability. Recall that a bounded behavioral response limits the average activity, a , to be at most the baseline level, $a = 1$, by imposing A1. In Theorem 4 (Supporting Information), we show that for any bounded behavioral response, there will be a second vaccination threshold, T_2 , which determines the stability of the baseline endemic equilibrium. The T_2 threshold is given by (Supporting Information),

$$T_2 = T_1 - \xi_F R_0 (\rho / \gamma + 1) \quad [1]$$

where ξ_F is a constant that depends on the properties of the reactivity function, F , near the baseline endemic equilibrium, R_0 is the average number of infections after contact in a fully susceptible population or *basic reproduction number*, and ρ and γ are rates (see Supporting Information). The ξ_F constant will often be positive, and in these cases the T_2 vaccination threshold will be lower than the T_1 threshold. In these cases, when the vaccination rate is higher than T_2 but less than T_1 , the baseline endemic equilibrium will be stable. For some reactivity functions, the constant ξ_F can be negative or zero, and for these reactivity functions the baseline endemic equilibrium will not be stable for any vaccination rate. Once the reactivity function, F , is specified, T_2 can be computed explicitly and we show how to compute T_2 along with several examples in the Supporting Information. This shows that even when the classical threshold for effective vaccination cannot be achieved, there can still be a substantial benefit at a lower vaccination rate. As long as the vaccination rate exceeds the new T_2 threshold, the baseline activity level will be stable (see examples Fig. 3).

When the vaccination rate is below both the T_1 and T_2 thresholds (e.g. early stages of a novel disease before a vaccination, $v = 0$) both the disease-free equilibrium and the baseline endemic are unstable and there is no stable equilibrium with baseline activity. In Theorem 6 (Supporting Information) we prove that there is at least one new equilibrium (Fig. 2b), which we term a “new normal” endemic equilibrium. Unlike the disease-free and baseline endemic equilibrium, the incidence rate at the new normal endemic equilibrium depends on the form of the behavioral feedback and implies long-term behavioral changes with activity level below baseline. When vaccination is below both thresholds, the stability of the new normal endemic cannot be determined universally, and it may have a complicated dependence on the details of the behavioral feedback and exhibit periodic cycles or chaos.

2. Examples

We emphasize that our results apply to any reactivity function, F , that satisfies A1 - A3. To illustrate our results we introduce three basic examples of reactivity functions.

$$F_{\text{linear}}(a, c) = w_1(1 - a) - w_2c \quad [2]$$

$$F_{\text{quadratic}}(a, c) = (1 - a)(w_1 - w_2c) \quad [3]$$

$$F_{\text{bilinear}}(a, c) = (1 - a)(w_1 - w_2c/a) \quad [4]$$

These functions all satisfy resilience and boundedness for any $w_1, w_2 > 0$ and we illustrate them in the top row of Fig. 3 for $w_1 = 0.1$ and $w_2 = 10$. The first two functions (2, 3) are important because they are the leading order approximation of any reactivity function. Note that the function $F_{\text{quadratic}}$ is quadratic in a since $c = aBsi$ and similarly F_{bilinear} is bilinear in a and i . In the Supporting Information we show that the simplest model, F_{linear} , does not have a baseline endemic equilibrium because $T_2 = T_1$. Both $F_{\text{quadratic}}$ and F_{bilinear} have $T_2 < T_1$, so for vaccination rates between these thresholds the baseline endemic is stable.




Fig. 3. Vaccination may increase or decrease infection rate depending on the form of the behavioral response. Relationship between activity, incidence, and vaccination rate for three example reactivity functions (columns). In the top row we illustrate zones of increasing (brown) and decreasing (purple) activity as a function of incidence; white indicates regions where activity is stationary (at least instantaneously). In the middle row the equilibrium activity is shown as a function of vaccination rate with colors indicating the disease-free, baseline endemic, and new normal regimes. The bottom row indicates the equilibrium incidence as a function of vaccination; stable equilibria are shown as solid lines and unstable equilibria as dashed lines. Note that when vaccination is less than T_2 (the new normal), increased vaccination may lead to either higher (bottom right) or lower (bottom left) infection rates depending on the reactivity function.

The primary difference between the three example reactivity functions is how quickly the equilibrium level of activity falls off as vaccination rate decreases (Fig. 3). For F_{linear} the activity versus vaccination curve is concave down, and this moderate response results in a new normal infection rate that increases rapidly as vaccination rate decreases (Fig. 3). For $F_{\text{quadratic}}$ equilibrium activity increases linearly with vaccination rate. This model has the interesting feature that a decrease in vaccination rate leads to a decrease in activity that maintains a constant level of infection in the new normal endemic. Finally, F_{bilinear} has the most

robust behavioral response, with a concave up increase in activity as vaccination rate increases. This response results in infection rate increasing as vaccination rates increase. Thus, when initially introducing a vaccination to a population the infection rate may initially increase until the critical vaccination rate threshold T_2 is reached and the baseline endemic is stabilized. This will especially be the case for a new vaccination that is being gradually rolled out, since a slow change in the vaccination rate can help keep the system near equilibrium as the new normal shifts.




Fig. 4. Introducing resilient activity accounts for a wide range of epidemic dynamics. Examples of the dynamics of the reactivity function F_{bilinear} with high vaccination (top left, $v > T_1$), moderate vaccination (top right, v between T_2 and T_1), and low vaccination (bottom left, $v < T_2$). Finally (bottom right) we simulate 300 days without any vaccination followed by a linear ramp up in vaccination between days 300 and 600 to a fixed moderate vaccination rate after day 600. Susceptible population, s (solid blue), activity level, a (dotted blue), and the phase transition level R_0^{-1} (dashed black) are scaled to the left axis while the infected population, i (solid red) is scaled to the right axis. (See equation Eq. (17) in the Supporting Information for details and Fig. S.3 for more examples.)

Finally, we note a fascinating feature of F_{bilinear} . If we consider the fraction of the population that remains susceptible to infection as approximately constant and set $1 - a$ as ‘distancing’, then we recover a form equivalent to the Lotka-Volterra predator-prey model where infections, i , play the role of prey and distancing, $1 - a$, plays the role of the predator (Supporting Information equation Eq. (12)). Oscillations are present at the beginning of the epidemic, when the susceptible population is large and almost constant. The oscillations are not damped, but they have a very slow decay due to the slow decrease in the susceptibles. Finally, the model exhibits a phase transition when the susceptible population drops below $\frac{1}{R_0}$, at which point the predator-prey oscillations cease and the system reverts to a more typical epidemic trajectory allowing the system to come to equilibrium. These oscillations depend on the vaccination rate (Fig. 4, Fig. S.3). This illustrates how behavioral feedback can lead to a wide range of epidemic dynamics including oscillations that are independent of any external (e.g. seasonal) forcing.

3. Discussion

The collective experience of recent global emergence events suggests that the conventional disease modeling framework is insufficient to predict the dynamics of the emergence of pathogens with severity or mortality that will drive behavioral

497 change. Notably, the standard SIR-model overestimates the
498 expected magnitude of an initial outbreak (in the absence of
499 knowledge about future individual or legislated behavioral
500 change) and consequently underestimates the expected time
501 to and magnitude of subsequent waves. Here we describe the
502 dynamics and equilibria of a novel SIR-type model with a
503 general formulation of behavioral feedbacks.

504 In the first year of the SARS-CoV-2 pandemic, before
505 the emergence of the first meaningful immune-escape variant
506 (Alpha in November 2020), many places (see Fig. 1) saw a
507 second wave of the original wild-type virus that was equal to,
508 or larger than, the magnitude of the initial emergent epidemic.
509 Behavioral change in response to the initial wave may have left
510 a sufficiently large susceptible population to permit a second,
511 larger wave when behavior and contact patterns returned
512 towards pre-SARS-CoV-2 levels. We find that behavioral
513 feedbacks that reduce contact rates in response to increasing
514 infection incidence can produce these novel dynamics in the
515 transient period of emergence. These behavioral feedbacks
516 also generate novel endemic equilibria characterized by either
517 persistent behavior restriction or a return to pre-emergence
518 behavior levels if vaccination is introduced and sufficiently
519 high.

520 We have shown that for a broad range of behavioral
521 feedbacks between the incidence of infection and activity that
522 contributes to transmission (e.g. contact rates or hygiene)
523 there exist two novel equilibria in addition to the classic
524 vaccine-based herd immunity threshold. While coordinated
525 behavioral interventions may be sufficient to drive incidence
526 to 0, e.g. as was seen for SARS-CoV-1 in 2004 (28), and
527 Ebola outbreaks (29) prior to the incorporation of vaccination
528 in outbreak response (30), such interventions alone cannot
529 stabilize the disease-free equilibrium if behavior exhibits
530 resilience. In the absence of vaccination there are no stable
531 equilibria that have a return to normal activity. SARS-
532 CoV-1 is the rare example of a pathogen that emerged
533 and was eradicated in the absence of a vaccine; however,
534 reintroduction from an animal reservoir remains possible (31)
535 and the relaxation of the behavioral interventions (28) render
536 the current disease-free state unstable (32).

537 The newly identified regime with vaccination between
538 T_2 and T_1 has substantial policy implications for emerging
539 infections and eradication. In the absence of vaccines, non-
540 pharmaceutical interventions remain an important part of
541 pandemic response for emerging infections and can be onerous.
542 The SARS-CoV-2 pandemic led to dramatic economic (33)
543 and educational (34, 35) consequences. Planning for a safe
544 return to pre-emergence activity can minimize these off-target
545 effects. While eradication may still be a goal, vaccination at
546 a level T_2 lower than the classic herd immunity threshold T_1
547 permits a return to pre-emergence activity while maintaining
548 a stable, non-zero incidence. Furthermore, attaining T_1 may
549 be challenging, particularly in the face of vaccine hesitancy,
550 vaccine administration logistics, or uncertainty about the
551 rate of loss of immunity. The existence of T_2 suggests
552 a midpoint goal for vaccination rate that can be used to
553 motivate vaccination efforts.

554 The existence of the vaccination regime between T_2 and T_1
555 may further be useful in policies for endemic infections. The
556 only benefits to vaccination in the standard SIR modeling
557 framework without behavioral feedbacks are reductions in
558

559 morbidity and mortality. This new model implies additional
560 societal change, in the form of the increased activity, that
561 may be stabilized at or above a lower vaccination threshold
562 T_2 . Whether this represents a societal benefit or not will be
563 highly epidemic specific. For example, vaccination rates above
564 T_2 may allow for relaxation of pre-screening requirements
565 and the costs inherent in such programs. Alternatively, one
566 could imagine an increase in risky behaviors, e.g. decreased
567 mask usage as vaccination increases. The positive correlation
568 between vaccination rate and equilibrium incidence under the
569 F_{bilinear} function could lead to population level assessment
570 of vaccine failure driven by the behavioral response. Any
571 specific predictions of such phenomena is speculative without
572 a mechanistic understanding of the explicit nature of the
573 feedbacks. For example Funk et al. (26) considered
574 that information, and thus behavioral response, may only
575 be available locally rather than globally and Weitz et al.
576 (20) considered that behavioral response may react to the
577 incidence of mortality rather than infection. The general
578 extension of the standard modeling framework for infectious
579 diseases that we have proposed offers a pathway to guide
580 more specific mechanistic investigations.

581 The description of these new equilibria represents a
582 novel advance for infectious disease and vaccination policy
583 development. A stable equilibrium provides a policy target
584 where the system is self-managing and self-maintaining.
585 The existence of such a stable target allows optimal policy
586 strategies to be formulated to reach that point. Policy
587 formulation without such an explicit goal requires iterative
588 trial-and-error which may incur economic or societal costs
589 that can undermine support for the process. Such adaptive
590 control strategies built upon iterative learning have a long
591 history (36–38) and are useful tools complemented by our
592 results showing that there are multiple advantageous stable
593 equilibria (disease-free or endemic) allowing a return to
594 normal behavior. In the face of uncertainty about the
595 feasibility of elimination, the endemic state with return to
596 normal behavior provides a valuable new policy target to
597 motivate action and guide policy development.

598 Materials and Methods

599 We will demonstrate the power of our approach on the most basic
600 infectious disease model. Thus, we start with the Susceptible, S ,
601 Infected, I , Recovered, R , (SIR) model for a well-mixed population
602 given by,

$$\begin{aligned} \dot{S} &= -\beta SI/N + \rho R - vS \\ \dot{I} &= \beta SI/N - \gamma I \\ \dot{R} &= \gamma I - \rho R + vS \\ N &= S + I + R. \end{aligned} \quad [5]$$

603 with transmission rate β , average duration of illness $1/\gamma$, and
604 a conserved population N . The parameter, v , represents the
605 vaccination rate, which moves population from susceptible, S , to
606 recovered, R . Conversely, the parameter, ρ , represents loss of
607 immunity, which moves population from recovered, R , back to
608 susceptible, S . Note that this model for vaccination implicitly
609 includes booster immunizations, since loss of immunity will
610 eventually move the previously vaccinated population back into the
611 susceptible class and the model assumes that they may eventually
612 be re-vaccinated or “boosted”. The specific interpretations of the
613 terms and parameters in Eq. (5) is provided only for aiding in
614 intuition. For example, instead of reinfection the source of new
615 susceptible population may be births (on a longer time scale),
616 or there may be other methods of removing people from the
617
618
619
620

susceptible population besides vaccination. The model and analysis presented here may be adaptable to such interpretations since our focus will be on the interaction of behavior and transmission.

The key to a frequency-based transmission model such as Eq. (5) is the nonlinear (S multiplies I) term for case incidence,

$$\beta SI/N$$

which quantifies the incidence rate of the disease. Following (39), we can break down the transmission rate, β , into a product of the rate of effective contact, a , and the probability of transmission given an effective contact, B , so that,

$$\beta = aB. \quad [6]$$

The *activity* rate, a , represents an *effective* rate that can include changes in behavior such as distancing or masking. To see this, it is worthwhile to note the formal descriptions of a and B from (39): a represents the rate of contacts that are of an appropriate type for transmission to be possible if one of the hosts is infectious, and B represents the probability that contact between an infectious and a susceptible host does in fact lead to transmission. Using these definitions, this framework allows for activity change that both reduces the rate of all contacts (e.g. distancing) or the rate of effective contacts (e.g. masking).

Substituting Eq. (6) into the formula for case incidence, C , we define,

$$C \equiv aBSI/N. \quad [7]$$

In this product S is the susceptible population who are having effective interactions with people at rate a . The probability of each interaction happening with an infected person is I/N , and B is the conditional probability that such an interaction with an infected person gives rise to infection. By separating β into its component factors, we see that it is much more reasonable to assume that B is constant (or at least that it changes on a longer time scale), whereas a behavioral response could be quite rapid and makes it likely that the rate of effective contact, a , could change on fast time scales. Notice that when $a = 1$ we have $\beta = B$ so we refer to $a = 1$ as the *baseline* level of activity.

We are now ready to quantify the various assumptions (A1-A3) that we will consider for the behavioral dynamics. First, *Reactivity* (Assumption A1) says that the rate of change of the activity parameter is a continuous function, F , that only depends on the current activity, a , and case incidence rate, c , which is the rate of new infections, $c \equiv C/N$ (here C is raw incidence and c is the incidence as a percentage of the total population). In other words, reactivity allows any behavioral dynamics of the form,

$$(A1 : Reactivity) \quad \dot{a} = F(a, c), \quad [8]$$

and we call F the *reactivity function*. The fact that there cannot be a ‘negative’ infection incidence implies that $a \geq 0$. When $a = 0$ the rate of change of activity cannot be negative. Thus, in addition to the form Eq. (8), reactivity also includes the assumption that $F(0, c) \geq 0$.

We can now quantify *Resilience* (Assumption A2), which states that when incidence is zero activity will increase. Here we come to one of the significant advantages of not specifying a model for activity. Recall that the baseline activity level is defined to be the level of activity that would be reached if the disease were removed and a long time were allowed for the activity to stabilize. Since the reactivity function, F , is not specified, we can always choose units for a such that the baseline activity level is $a = 1$ by incorporating the change of units into the definition of the reactivity function.

When $a = 1$, transmissibility during contacts reflects the baseline contagiousness of the disease. All we are assuming here is that there is *some* baseline value for activity, and then choosing units which re-scale that value to one. Thus, without loss of generality, resilience can be quantified as,

$$(A2 : Resilience) \quad F(a, 0) > 0 \text{ when } a < 1 \text{ and } F(1, 0) = 0, \quad [9]$$

which implies that when activity is below baseline activity ($a < 1$) and incidence is zero ($c = 0$) activity will increase ($\dot{a} = F(a, 0) > 0$). We also need to assume that $F(1, 0) = 0$ to insure that baseline activity is stationary when there is no incidence. The condition Eq. (9) is all that is required when we are also assuming boundedness (A3), but for technical reasons when the behavior

is not bounded we will also assume $F(a, 0) < 0$ when $a > 1$. Note that we have assumed we are working in units where $a = 1$ corresponds to baseline activity, so $a < 1$ means any level of activity that is below baseline and $a > 1$ means activity is above baseline. Moreover, $F(a, 0) > 0$ means that, when there is no incidence, the rate of change of activity is positive, so activity is increasing, and this captures the assumption of resilience. Resilience also includes the assumption that baseline activity ($a = 1$) is stationary when there is zero incidence ($c = 0$); this assumption is captured by the equation $F(1, 0) = 0$ in Eq. (9).

Lastly, *Boundedness* (Assumption A3) says that the baseline activity level (averaged over the whole population) is the highest level possible, meaning that $a \leq 1$. This means that when $a = 1$ we must have

$$(A3 : Boundedness) \quad F(1, c) \leq 0 \quad [10]$$

otherwise the activity would increase beyond the boundedness limit of $a = 1$.

Thus, we consider the following infection model that incorporates vaccination, loss of immunity, and arbitrary behavioral dynamics,

$$\begin{aligned} \dot{S} &= -aBSI/N + \rho R - vS \\ \dot{I} &= aBSI/N - \gamma I \\ \dot{R} &= \gamma I - \rho R + vS \\ \dot{a} &= F(a, aBSI/N^2) \\ N &= S + I + R \end{aligned} \quad [11]$$

In order to remove the algebraic equation $N = S + I + R$ we rewrite the model in terms of population fractions. Setting $s = S/N$, $i = I/N$, and $r = R/N$ we have $s + i + r = 1$ and $\dot{s} + \dot{i} + \dot{r} = 0$. Moreover, we can remove the equation for the recovered population fraction, r , by setting $r = 1 - s - i$ in the remaining equations. Thus, the following equations govern the fractions of the population,

$$\begin{aligned} \dot{s} &= -aBsi + \rho(1 - s - i) - vs \\ \dot{i} &= aBsi - \gamma i \\ \dot{a} &= F(a, aBsi). \end{aligned} \quad [12]$$

In these units, the basic reproduction number is $R_0 \equiv B/\gamma$, which defines the expected number of secondary infections due to the initial infection in a completely naive population.

ACKNOWLEDGMENTS. Supported by US NIH Director’s Transformative Award 1R01AI145057.

1. WO Kermack, AG McKendrick, A contribution to the mathematical theory of epidemics. *Proc. royal society london. Ser. A. Containing papers a mathematical physical character* **115**, 700–721 (1927).
2. RM Anderson, RM May, *Infectious diseases of humans: dynamics and control*. (Oxford university press), (1992).
3. JC Miller, A note on the derivation of epidemic final sizes. *Bull. mathematical biology* **74**, 2125–2141 (2012).
4. MI Meltzer, Modeling in real time during the ebola response. *MMWR supplements* **65** (2016).
5. N Ferguson, et al., Report 9: Impact of non-pharmaceutical interventions (npis) to reduce covid-19 mortality and healthcare demand. *Publ. Online, Imp. Coll. Lond. COVID-19 Sch. Public Heal.* (2020).

6. CDC, Covid-19 pandemic planning scenarios (2021).
7. A Bleichrodt, et al., Real-time forecasting the trajectory of monkeypox outbreaks at the national and global levels, july–october 2022. *BMC medicine* **21**, 1–20 (2023).
8. A Endo, et al., Heavy-tailed sexual contact networks and monkeypox epidemiology in the global outbreak, 2022. *Science* **378**, 90–94 (2022).
9. AC Lowen, J Steel, Roles of humidity and temperature in shaping influenza seasonality. *J. virology* **88**, 7692–7695 (2014).
10. PE Fine, JA Clarkson, Measles in england and wales—i: an analysis of factors underlying seasonal patterns. *Int. journal epidemiology* **11**, 5–14 (1982).
11. CO Buckee, et al., Aggregated mobility data could help fight covid-19. *Science* **368**, 145–146 (2020).

745 12. G Bonaccorsi, et al., Economic and social consequences of human mobility restrictions under covid-19. *Proc. Natl. Acad. Sci.* **117**, 15530–15535 (2020).
 746 13. MS Lau, et al., Characterizing superspreading events and age-specific infectiousness of sars-cov-2 transmission in georgia, usa. *Proc. Natl. Acad. Sci.* **117**, 22430–22435 (2020).
 747 14. MJ Keeling, P Rohani, *Modeling Infectious Diseases in Humans and Animals*. (Princeton University Press), (2008).
 748 15. E Dong, H Du, L Gardner, An interactive web-based dashboard to track covid-19 in real time. *The Lancet infectious diseases* **20**, 533–534 (2020).
 749 16. CT Bauch, DJ Earn, Vaccination and the theory of games. *Proc. Natl. Acad. Sci.* **101**, 13391–13394 (2004).
 750 17. B Buonomo, A d’Onofrio, D Lactignola, Global stability of a sir epidemic model with information dependent vaccination. *Math. biosciences* **216**, 9–16 (2008).
 751 18. TC Reluga, Game theory of social distancing in response to an epidemic. *PLoS computational biology* **6**, e1000793 (2010).
 752 19. T Ash, AM Bento, D Kaffine, A Rao, Al Bento, Disease-economy trade-offs under alternative epidemic control strategies. *Nat. Commun.* **13**, 1–14 (2022).
 753 20. JS Weitz, SW Park, C Eksin, J Dushoff, Awareness-driven behavior changes can shift the shape of epidemics away from peaks and toward plateaus, shoulders, and oscillations. *Proc. Natl. Acad. Sci.* **117**, 32764–32771 (2020).
 754 21. AV Tkachenko, et al., Stochastic social behavior coupled to covid-19 dynamics leads to waves, plateaus, and an endemic state. *Elife* **10**, e68341 (2021).
 755 22. C Bauch, A d’Onofrio, P Manfredi, Behavioral epidemiology of infectious diseases: an overview. *Model. interplay between human behavior spread infectious diseases* pp. 1–19 (2013).
 756 23. EP Fenichel, et al., Adaptive human behavior in epidemiological models. *Proc. Natl. Acad. Sci.* **108**, 6306–6311 (2011).
 757 24. A Rizzo, M Frasca, M Porfiri, Effect of individual behavior on epidemic spreading in activity-driven networks. *Phys. Rev. E* **90**, 042801 (2014).
 758 25. JM Epstein, J Parker, D Cummings, RA Hammond, Coupled contagion dynamics of fear and disease: mathematical and computational explorations. *PLoS one* **3**, e3955 (2008).
 759 26. S Funk, E Gilad, C Watkins, VA Jansen, The spread of awareness and its impact on epidemic outbreaks. *Proc. Natl. Acad. Sci.* **106**, 6872–6877 (2009).
 760 27. RF Arthur, JH Jones, MH Bonds, Y Ram, MW Feldman, Adaptive social contact rates induce complex dynamics during epidemics. *PLoS computational biology* **17**, e1008639 (2021).
 761 28. DM Bell, et al., Public health interventions and sars spread, 2003. *Emerg. infectious diseases* **10**, 1900 (2004).
 762 29. TD Kirsch, et al., Impact of interventions and the incidence of ebola virus disease in liberia - implications for future epidemics. *Heal. Policy Plan.* **32**, 205–214 (2016).
 763 30. JA Walldorf, et al., Considerations for use of ebola vaccine during an emergency response. *Vaccine* **37**, 7190–7200 (2019).
 764 31. DM Morens, AS Fauci, Emerging pandemic diseases: how we got to covid-19. *Cell* **182**, 1077–1092 (2020).
 765 32. K Monaghan, *SARS: Down but still a threat*. (National Intelligence Council) Vol. 3, (2003).
 766 33. J Chen, et al., Epidemiological and economic impact of covid-19 in the us. *Sci. reports* **11**, 1–12 (2021).
 767 34. S Hammerstein, C König, T Dreisörner, A Frey, Effects of covid-19-related school closures on student achievement—a systematic review. *Front. psychology* **12**, 746289 (2021).
 768 35. J Hoofman, E Secord, The effect of covid-19 on education. *Pediatr. Clin.* **68**, 1071–1079 (2021).
 769 36. K Shea, MJ Tildesley, MC Runge, CJ Fonnesebeck, MJ Ferrari, Adaptive management and the value of information: learning via intervention in epidemiology. *PLoS biology* **12**, e1001970 (2014).
 770 37. DA Keith, TG Martin, E McDonald-Madden, C Walters, Uncertainty and adaptive management for biodiversity conservation (2011).
 771 38. BK Williams, Adaptive management of natural resources—framework and issues. *J. environmental management* **92**, 1346–1353 (2011).
 772 39. M Begon, et al., A clarification of transmission terms in host-microparasite models: numbers, densities and areas. *Epidemiol. & Infect.* **129**, 147–153 (2002).
 773 40. MJ Ferrari, et al., The dynamics of measles in sub-saharan africa. *Nature* **451**, 679–684 (2008).

S. Supporting Information: Stabilizing the return to normal behavior in an epidemic

S.1. Theorems and Proofs. We first show that the disease dynamics are contained in the region shown in Fig. 2 and can never leave. Under the assumptions A1-A3, there is a region, Ω , (Fig. 2), such that if the system starts within Ω , then the system will remain inside Ω at all future times (Lemma 1 below). This property ensures that no populations become negative and that the activity variable a stays within its prescribed range $0 \leq a \leq 1$. Thus, all long-term behavior will be determined by dynamical attractors which could be equilibria, cycles, or even chaos (40), which must lie entirely within Ω .

Lemma 1. Under the dynamics of Eq. (12), the set

$$\Omega = \{(s, i, a) \in [0, 1]^3 : s + i \leq 1\}$$

is invariant when F is resilient Eq. (9) and bounded Eq. (10).

Proof. Note that when $a = 0$ we have $F(0, 0) \geq 0$ by Eq. (9) (resilience), and when $a = 1$ we have $F(1, Bsi) \leq 0$ by Eq. (10) (boundedness). So the a component is always pointing into Ω and we need only consider the (s, i) variables. When $i = 0$ we have $\dot{i} = 0$ and when $\dot{s} = 0$ we have $\dot{s} = \rho(1 - i) \geq 0$, so along each of these boundaries the vector field is pointing into the set Ω . Finally, we check the boundary $s + i = 1$, where $\dot{s} = aBs(1 - s) - vs$ and $\dot{i} = aBs(1 - s) + \gamma(1 - s)$ so that $(\dot{s}, \dot{i}) \cdot (1, 1) = -\gamma + (\gamma - v)s < 0$ meaning that the vector field is always pointing into the set (since $(1, 1)$ is the outward pointing normal vector to the boundary $s + i = 1$ and the inner product of the vector field with this outward pointing normal is negative). \square

The lemma shows that for any reactive behavioral response function, F , which is resilient and bounded, the dynamics of the disease will always preserve some natural constraints that we expect. For example, the variables s , i , and r represent fractions of the population and so they should always be between zero and one and they should always sum to one. If we view the variables s and i as lying in a plane, these constraints imply that they must always lie in a triangle as shown in Fig. S.1. If we now add the activity variable in the vertical dimension (coming out of the plane of the paper in Fig. S.1), we see that we have a solid shape with horizontal triangular cross sections as shown in Fig. 2.

Another natural limitation is that the activity variable, a , cannot be negative, since that would imply that members of the infected population are moving directly back into the susceptible population. The model does allow loss of immunity and re-infection through the ρ parameter, but as an axiom we do not permit ‘negative’ infections. It would also be possible to allow immediate re-infection by using a term proportional to the recovered and infected populations, however, for simplicity we assume here that recovery imputes at least a temporary immunity, and the length of time of this immunity is controlled by ρ . Altogether, taking the solid shape with triangular horizontal cross-sections and restricting the height to be between zero and one we have the gray solid shape shown in Fig. 2 which we call the *domain*, Ω , of the dynamics.

The way we constructed the domain in Fig. 2, the dynamics of the disease *should* be constrained to that region for all time, however, a poorly specified dynamical model could allow the dynamics to ‘escape’ the domain, violating our axioms. So our first result is Lemma 1, which shows that for any resilient and bounded activity function, the state cannot escape and is confined to the domain in Fig. 2 forever. This result, although a bit cumbersome to check, simply requires showing that along each surface of the solid shape all the arrows of the dynamics are always pointing inwards. Notice that our key assumptions of resilience and boundedness concern the boundaries of the domain. For example, resilience says that $F(a, 0) > 0$, meaning that it only constrains what happens when the rate of incidence, $c = aBs$, is zero, which is only true when either $i = 0$ or $s = 0$ or $a = 0$, and these are the front square surface, left square surface, and bottom triangular surface of the domain respectively. Resilience says that along each of these three surfaces, the vertical component of the arrows that define the dynamics are pointing upwards, towards increasing activity. Boundedness says that $F(1, c) \leq 0$, and activity is only equal to 1




Fig. S.1. Equilibria and dynamics projected on the susceptible/infected plane. Here we show three horizontal slices (fixed activity slices) from the domain, Ω , shown in Fig. 2. The top left and top right slices show the top of the domain ($a = 1$) with high and moderate vaccination rates respectively. The bottom slice is from the middle of the domain when the vaccination rate is very low and only the new normal endemic is stable. Note that the flow arrows, curves, and intersections shown in these cross sections depend on the disease parameters but are independent of the behavioral dynamics (except for the activity level, a , of the new normal endemic shown in the bottom panel).

along the top triangular surface of the domain. So boundedness implies that along this top surface the vertical component of the arrows that define the dynamics must not point up (they can point down or horizontally or be zero).

Our main result on equilibria is stated next, and will be derived in stages.

Theorem 2. Consider the reactive dynamics Eq. (12) for any twice differentiable $F : [0, 1]^2 \rightarrow \mathbb{R}$ that is both resilient and bounded. Then,

- There is only one disease-free equilibrium, and it has baseline activity ($a = 1$).

- When the vaccination rate is high enough, namely,

$$v > T_1 \equiv \rho(R_0 - 1)$$

the disease-free equilibrium is the only equilibrium in Ω and it is locally asymptotically stable.

- When $v < T_1$ the disease-free equilibrium is unstable and there exists a unique baseline endemic equilibrium ($a = 1$) and at least one new normal endemic equilibrium ($a < 1$).

- The baseline endemic equilibrium is stable when,

$$v > T_2 \equiv \rho(R_0 - 1) + \xi_F R_0(\rho/\gamma + 1)$$

where ξ_F is a constant that depends on F .

- If the vaccination rate is below T_2 then the only stable equilibria are new normal endemic equilibria ($a < 1$) and at least one new normal endemic equilibrium must exist.

Theorem 2 follows immediately from Theorems 3-6 below. For the T_2 threshold, we do not have an explicit formula for the constant ξ_F , however we will show that it is given by $\xi_F = \frac{F_a(1,0)}{F_{ac}(1,c)}$ for some $c \in (0, \gamma i)$, and we will show that $F_a(1,0) < 0$ so when $F_{ac}(1,c) > 0$ we have $T_2 < T_1$. It is also possible to have $T_2 \geq T_1$ and in these cases the baseline endemic is never stable. In practice, it is straightforward to find the second vaccination threshold by solving the equation $F_a\left(1, \frac{\rho(R_0-1)-T_2}{R_0(\rho/\gamma+1)}\right) = 0$ for T_2 . For examples that show how to find T_2 see Section S.2.

To motivate the basic dichotomy for equilibria in terms of infection rate (disease-free vs. endemic), note that setting $di/dt = 0$ immediately implies that either $i = 0$ or $aBs - \gamma = 0$. The former

case is the disease-free equilibrium, and, in the latter case, one can show that the fraction of the infected population will be,

$$i = \frac{(a-1)R_0\rho + \rho(R_0-1) - v}{aR_0(\gamma + \rho)}. \quad [13]$$

This cannot be negative, and since $a \leq 1$ the first term in the numerator is negative or zero, so we immediately see that when the vaccination rate is greater than $\rho(R_0 - 1)$ there cannot be any equilibria of the form Eq. (13). At this point we have only made Assumption A1, and we already have a universal vaccination threshold which we call,

$$T_1 \equiv \rho(R_0 - 1). \quad [14]$$

When the vaccination rate is above T_1 , the only possible equilibrium is the disease-free equilibrium, and this holds for any reactivity function F .

In order to analyze the stability of equilibria, we will frequently make use of the Jacobian matrix of partial derivatives of the right hand side of Eq. (12) which is,

$$\begin{pmatrix} -aBi - v - \rho & -aBs - \rho & -Bsi \\ aBi & aBs - \gamma & Bsi \\ aBiF_c & aBsF_c & F_a + BsiF_c \end{pmatrix}$$

where F_a and F_c are shorthand for partial derivatives and are evaluated at $(a, aBs i)$ in the Jacobian.

Theorem 3 (Disease-Free Equilibrium). For any reactive dynamics of the form Eq. (12), every disease-free equilibrium has $s = \frac{\rho}{\rho+v}$ and the equilibrium activity level solves $F(a,0) = 0$. When the vaccination rate, v , is below the universal threshold, $T_1 \equiv \rho(R_0 - 1)$ all disease-free equilibria are unstable.

If we also assume that the behavior is resilient, there is only one disease-free equilibrium. It has baseline activity ($a = 1$), and is stable when the vaccination rate is greater than T_1 .

Proof. Setting the equations in Eq. (12) equal to zero and substituting $i = 0$ for a disease-free equilibrium we immediately find that $B = b = 0$ and $s = \frac{\rho}{\rho+v}$ and $F(a,0) = 0$. The Jacobian of the right hand side of Eq. (12) at this equilibrium is,

$$\begin{pmatrix} -v - \rho & -\frac{B\rho}{v+\rho} - \rho & 0 \\ 0 & \frac{B\rho}{v+\rho} - \gamma & 0 \\ 0 & F_c(a,0) \frac{B\rho}{\rho+v} & F_a(a,0) \end{pmatrix}$$

and the eigenvalues are $\lambda_1 = -v - \rho$, $\lambda_2 = \frac{B\rho}{\rho+v} - \gamma$, and $\lambda_3 = F_a(a,0)$. When $v < T_1$ we have $\lambda_2 > 0$ which implies that the equilibrium is unstable. Since this Jacobian applies to any disease-free equilibrium, this means that a vaccination rate below T_1 implies that any disease-free equilibrium will be unstable.

If we assume the behavioral dynamics are resilient, we have immediately that $F(1,0) = 0$ so that there is a disease-free equilibrium with baseline activity, $a = 1$. Moreover, resilience says that $F(a,0) > 0$ whenever $a < 1$, so there is only one disease-free equilibrium, and it has baseline activity. To analyze the stability of this disease-free equilibrium, note that $F(1,0) = 0$ implies

$$\lambda_3 = F_a(1,0) = \lim_{\delta \rightarrow 0^+} \frac{F(1,0) - F(1-\delta,0)}{\delta} = \lim_{\delta \rightarrow 0^+} \frac{-F(1-\delta,0)}{\delta} \leq 0$$

where the final inequality follows from the fact that $F(1-\delta,0) > 0$ by resilience. So when $F_a(1,0) < 0$ and $v > T_1$, all the eigenvalues of the Jacobian are negative and the disease-free equilibrium is asymptotically stable. The cases of $v = T_1$ and $F_a(1,0) = 0$ are special cases known as non-hyperbolic equilibria, and stability in these cases have to be determined separately from the general stability analysis. Since it is unlikely that the vaccination rate would be exactly equal to T_1 , we will leave that case aside (which is why we assume v is strictly less than T_1 in the statement of the result). However, to avoid additional assumptions on F , we must also consider the non-hyperbolic case when $F_a(1,0) = 0$.

While the stability of non-hyperbolic equilibria is typically difficult to analyze, in the case of a bounded behavioral model we can prove that the disease-free equilibrium is still stable even

when $F_a(1, 0) = 0$ (as long as $v > T_1$). To show this, we will use a technical notion of stability known as Lyapunov stability, which says that for any small region around the equilibrium, we can find an even smaller region such that if you start in the smaller region you will never leave the first region. We will prove this by finding $\epsilon_0 > 0$ such that for any $\epsilon \in (0, \epsilon_0)$ we can find an invariant open set inside the ϵ -ball that contains the equilibrium. The basic intuition is that because the system has two negative eigenvalues, when we get close enough to the equilibrium, the first two components of the vector field will be pointing into a cylinder surrounding the equilibrium. Moreover, because of resilience, the vector field must be pointing upwards on the bottom of the cylinder (as long as the cylinder is taken sufficiently small), and assuming boundedness the dynamics cannot leave the top of cylinder. Thus, the cylinder will be invariant under the dynamics.

Fix $\epsilon > 0$, then for each $a \in (1 - \epsilon, 1)$ we have $F(a, 0) > 0$ by resilience, and since F is continuous there must exist some δ_a such that $F(a, c) > 0$ for all $c < \delta_a$ and we can choose δ_a to be a continuous function of a . Let $\delta = \max_{a \in [1 - \epsilon, 1]} \{\min\{\epsilon - (1 - a), \delta_a\}\}$, which exists since it is a continuous function on a compact set, and let \bar{a} be the largest value of a with $\delta_a = \delta$. We can now define a cylindrical region $\mathcal{O} = \{(s, i, a) : \|(s, i) - (\rho/(\rho + v), 0)\| < \delta/\max\{1, B\}, |a - 1| < 1 - \bar{a}\}$. To see that \mathcal{O} is invariant, note that the bottom of the cylinder is the set with $a = \bar{a}$ and $\delta_a = \delta$, so $F(\bar{a}, c) > 0$ for all $c < \delta$ and $\|(s\rho/(\rho + v), i)\| < \delta/B$ so we have $c = aBsi \leq B\|(s, i) - (0, 0)\| < \delta$ (since $a, s, \rho/(\rho + v) \leq 1$ and $i < \delta/B$) so each point on the bottom of the cylinder is within the radius where $\dot{a} > 0$, so the vector field is pointing up into the cylinder. Note that a similar argument can be made for the top of the cylinder using the fact that resilience includes $F(a, 0) < 0$ when $a > 1$, or simply using boundedness in which case the top of the cylinder is just $a = 1$.

Next we need to show that the vector field along the walls of the cylinder is pointing into the cylinder, and this will require taking $\epsilon > 0$ sufficiently small. We first use Taylor's theorem to argue that sufficiently close the equilibrium the vector field looks close to its linearization namely, writing Eq. (12) as $\dot{x} = f(x)$ where $x = (s, i, a)^\top$ and calling the equilibrium $x_0 = (s, i, a)^\top = (\rho/(\rho + v), 0, 1)^\top$ we have, $f(x_0) = 0$ so Taylor's theorem says,

$$f(x) = Df(x_0)(x - x_0) + R(x)\|x - x_0\|$$

where $R(x) \rightarrow 0$ as $x \rightarrow x_0$. Now take the vector $x - x_0$ which points away from the equilibrium and orthogonally decompose it as $x - x_0 = v + v^a$, where v^a is the component in the a -direction and v is the projection of $x - x_0$ into the (s, i) -plane. Taking the inner product v we have

$$v \cdot f(x) = v^\top Df(x_0)(x - x_0) + v \cdot R(x)\|x - x_0\|$$

and in the non-hyperbolic case

$$Df(x_0)(x - x_0) = Df(x_0)v + Df(x_0)v^a = Df(x_0)v,$$

so writing $\hat{v} = v/\|v\|$ we have,

$$\left| \frac{\hat{v} \cdot f(x)}{\|x - x_0\|} - \hat{v}^\top Df(x_0)\hat{v} \frac{\|v\|}{\|x - x_0\|} \right| \leq \|R(x)\|.$$

Now note that along the walls of the cylinder \mathcal{O} we have $\|v\|/\|x - x_0\| < \frac{\delta}{\epsilon B} < \frac{1}{B}$ (since $\delta < \epsilon$), so choose $\epsilon_0 > 0$ sufficiently small so that for all $\|x - x_0\| < \epsilon$ we have $\|R(x)\| < -\max\{\lambda_1, \lambda_2\}$. Then $\|R(x)\| \leq |\hat{v}^\top Df(x_0)\hat{v}|$ (since the latter is the Raleigh quotient for $Df(x_0)$ orthogonal to $(0, 0, 1)^\top$ and $\lambda_1, \lambda_2 < 0$ are its eigenvalues in that subspace) and it follows that $\frac{\hat{v} \cdot f(x)}{\|x - x_0\|} < 0$ (since $\|R(x)\|$ is sufficiently small that it must have the same sign as $\hat{v}^\top Df(x_0)\hat{v}$). Notice that \hat{v} is the orthogonal projection into the (s, i) -plane of the vector pointing away from the equilibrium (and is thus normal to the cylinder wall pointing outwards). Thus the vector field $f(x)$ must be pointing into the cylinder \mathcal{O} , since its inner product with \hat{v} is negative.

So we conclude that for resilient behavior with $F_a(1, 0) < 0$ the disease-free equilibrium is asymptotically stable, and even when $F_a(1, 0) = 0$ the disease-free equilibrium is Lyapunov stable. \square

Thus we have seen that the disease-free equilibrium requires stabilizing baseline activity ($a = 1$), and for resilient behavioral

dynamics a sufficient condition is a high enough vaccination rate, $v > T_1$.

Next we turn to equilibria that have nonzero disease levels. Assume there is an equilibrium (s, i, a) of Eq. (12) with $i > 0$. Solving for the equilibrium yields

$$s = \frac{\gamma}{aB}, \quad i = \frac{(a - 1)B\rho + \gamma[(R_0 - 1)\rho - v]}{aB(\gamma + \rho)}. \quad [15]$$

Notice that since $a \leq 1$, having a vaccination rate $v > \rho(R_0 - 1)$ implies that $i < 0$, so no endemic equilibrium exists. Recall that this parameter range is exactly where the disease-free equilibrium is stable (Theorem 2).

On the other hand, if $v < \rho(R_0 - 1)$, then for every value of a satisfying $F(a, c) = 0$ an endemic equilibrium (s, i, a) exists. In other words, these endemic equilibria are created as the vaccination rate v drops through the stability threshold $T_1 = \rho(R_0 - 1)$.

Theorem 4 (Baseline Endemic Equilibrium). *For any F the model Eq. (12) has at most two equilibria with baseline activity ($a = 1$) in Ω , namely, the disease-free equilibrium from Theorem 3, and an endemic equilibrium with $s = R_0^{-1}$ and $i = \frac{\rho(R_0 - 1) - v}{R_0(\rho + \gamma)}$. This second equilibrium is called the baseline endemic equilibrium, it exists when $F(1, \gamma i) = 0$, and it is only in Ω when $v < \rho(R_0 - 1)$ (meaning the disease-free equilibrium is unstable). When F is Bounded (satisfies Eq. (10)), this endemic equilibrium is stable if and only if $F_a(1, \gamma i) \leq 0$. Moreover, there exists $c \in (0, \gamma i)$ such that the stability condition is,*

$$v \geq \rho(R_0 - 1) + \frac{F_a(1, 0)}{F_{ac}(1, c)}(\rho/\gamma + 1)R_0$$

and the equilibrium is locally asymptotically stable if the inequality is strict.

Proof. Setting $a = 1$ the equation $\dot{i} = 0$ immediately reveals that either $i = 0$ (the disease-free equilibrium) or $s = \gamma/B = R_0^{-1}$. Setting $\dot{s} = 0$ we find $i = \frac{\rho(R_0 - 1) - v}{R_0(\rho + \gamma)}$ and the instantaneous case rate is $C/N = Bsi = \gamma i$. Now, by Eq. (10), for any $\delta > 0$ we have, $F(1, \gamma i + \delta) \leq 0$ and $F(1, \gamma i - \delta) \leq 0$, and since we are at equilibrium we have $F(1, \gamma i) = 0$ which implies

$$F_c(1, \gamma i) = \lim_{\delta \rightarrow 0^+} \frac{F(1, \gamma i + \delta) - F(1, \gamma i)}{\delta} = \lim_{\delta \rightarrow 0^+} \frac{F(1, \gamma i + \delta)}{\delta} \leq 0$$

$$F_c(1, \gamma i) = \lim_{\delta \rightarrow 0^+} \frac{F(1, \gamma i) - F(1, \gamma i - \delta)}{\delta} = \lim_{\delta \rightarrow 0^+} \frac{-F(1, \gamma i - \delta)}{\delta} \geq 0$$

so we have $F_c(1, \gamma i) = 0$. This fact simplifies the Jacobian at the equilibrium which becomes

$$\begin{pmatrix} -Bi - v - \rho & -\gamma - \rho & \gamma i \\ Bi & 0 & -\gamma i \\ 0 & 0 & F_a(1, \gamma i) \end{pmatrix}$$

with characteristic equation

$$0 = (F_a(1, \gamma i) - \lambda)(\lambda^2 + \lambda(v + \rho + Bi) + Bi(\gamma + \rho)) = (F_a(1, \gamma i) - \lambda) \times$$

$$\left(\lambda^2 + \lambda \left(v + \rho + \frac{\rho B - \rho\gamma - \gamma v}{\rho + \gamma} \right) + \rho B - \rho\gamma - \gamma v \right)$$

Thus, $\lambda = F_a(1, \gamma i)$ is an eigenvalue and the remaining two eigenvalues are

$$\lambda = -(v + \rho + Bi)/2 \pm \sqrt{(v + \rho + Bi)^2/4 - Bi(\gamma + \rho)}$$

$$= -\frac{1}{2} \left(v + \rho + \frac{\rho B - \rho\gamma - \gamma v}{\rho + \gamma} \right) \pm$$

$$\sqrt{\frac{1}{4} \left(v + \rho + \frac{\rho B - \rho\gamma - \gamma v}{\rho + \gamma} \right)^2 - (\rho B - \rho\gamma - \gamma v)} \quad [16]$$

since all these variables and parameters are positive, from the first expression for λ we have

$$\operatorname{Re} \left(\sqrt{(v + \rho + Bi)^2/4 - Bi(\gamma + \rho)} \right) < (v + \rho + Bi)/2$$

1117 so that the real part of both of these eigenvalues are negative.
 1118 Thus when $F_a(1, \gamma i) > 0$ this equilibrium is unstable and when
 1119 $F_a(1, \gamma i) < 0$ it is stable. Now by the mean value theorem, there
 1120 exists $c \in (0, \gamma i)$ such that,

$$1121 \quad F_a(1, \gamma i) = F_a(1, 0) + F_{ac}(1, c)\gamma i < 0$$

1122 and plugging in for i and solving for the vaccination rate we find
 1123 $v > \rho(R_0 - 1) + \frac{F_a(1,0)}{F_{ac}(1,c)}(\rho/\gamma + 1)R_0$. \square

1124 Recall that $F_a(1, 0) \leq 0$, so assuming $F_{ac}(1, c) > 0$, Theorem
 1125 4 establishes the existence of a lower vaccination threshold for
 1126 stabilizing the baseline endemic equilibrium. Now we turn to the
 1127 existence of a new normal ($a \neq 1$) endemic ($i \neq 0$) equilibrium.

1128 Notice that in the proof of Theorem 4 there is the possibility
 1129 of complex eigenvalues meaning that the dynamics near the
 1130 baseline endemic equilibrium would behave like a damped harmonic
 1131 oscillator. However, this oscillatory behavior is entirely due to the
 1132 SIR dynamics, and does not arise from the behavioral dynamics.
 1133 Behavioral oscillations are also possible, but will depend on the
 1134 specific form of the F function that defines the behavioral dynamics.
 1135 Moreover, behavioral oscillations will only arise from the new
 1136 normal endemic equilibria addressed in Theorem 6 below. Before
 1137 considering new normal endemic equilibria, we first characterize
 1138 the possible oscillations of the baseline endemic equilibrium.

1139 **Corollary 5.** *The dynamics near the baseline endemic equilibrium
 1140 from Theorem 4 will be oscillatory when B is in the range*

$$1141 \quad 2 \left(1 - \sqrt{\frac{\gamma}{\rho + \gamma}} \right) \frac{(\rho + \gamma)^2}{\rho} - \rho < B < 2 \left(1 + \sqrt{\frac{\gamma}{\rho + \gamma}} \right) \frac{(\rho + \gamma)^2}{\rho} - \rho$$

1142 and the vaccination rate is sufficiently low, namely

$$1143 \quad v \leq - \left(B + \rho + 2\gamma \frac{(\rho + \gamma)^2}{\rho^2} \right) + 2 \frac{(\rho + \gamma)^2}{\rho^2} \sqrt{B\rho^2/(\rho + \gamma) + \gamma^2}.$$

1144 The damping rate and frequency of the oscillation near the
 1145 equilibrium are given by,

$$1146 \quad \text{Re}(\lambda) = -\frac{1}{2} \left(\frac{\rho}{\rho + \gamma} \right) (B + v + \rho)$$

$$1147 \quad \text{Im}(\lambda) = \sqrt{\rho B - \rho\gamma - \gamma v - \frac{1}{4} \left(\frac{\rho}{\rho + \gamma} \right)^2 (B + v + \rho)^2}$$

1148 (where λ is the complex eigenvalue from the proof of Theorem 4)
 1149 and the damping ratio of the oscillation near the equilibrium is,

$$1150 \quad \zeta \equiv \frac{|\text{Re}(\lambda)|}{\sqrt{\text{Re}(\lambda)^2 + \text{Im}(\lambda)^2}} = \left(\frac{\rho}{\rho + \gamma} \right) \frac{(B + v + \rho)}{2\sqrt{\rho B - \rho\gamma - \gamma v}}.$$

1151 The proof of Corollary 5 follows directly from the formulae for
 1152 the eigenvalues in Theorem 4 by elementary (albeit cumbersome)
 1153 algebra and is omitted.

1154 **Theorem 6** (“New Normal” Endemic Equilibria). *Assume that*
 1155 $v < \rho(R_0 - 1)$ (which implies that the disease-free equilibrium is
 1156 unstable) and that the baseline endemic equilibrium is unstable.
 1157 For any F that is Resilient and Bounded (meaning F satisfies
 1158 Eq. (9) and Eq. (10)) the dynamics of Eq. (12) have at least
 1159 one new normal endemic equilibrium in Ω with $a \neq 1$ and $i \neq 0$.
 1160 Conversely, when $v \geq \rho(R_0 - 1)$ there are no new normal endemic
 1161 equilibria in Ω .

1162 *Proof.* Since we are assuming $i \neq 0$ and $a \neq 1$, setting $\dot{i} = 0$ we
 1163 find $s = \frac{\gamma}{aB}$ and plugging this into $0 = \dot{s}$ we find $i = \frac{\rho(aR_0 - 1) - v}{(\rho + \gamma)aR_0}$.
 1164 Thus, at any equilibrium we can write

$$1165 \quad 0 = \dot{a} = F(a, aBsi) = F(a, \gamma i) = F \left(a, \gamma \frac{\rho(aR_0 - 1) - v}{(\rho + \gamma)aR_0} \right)$$

1166 so we define a curve $\Gamma : [0, 1] \rightarrow \mathbb{R}^2$ given by
 1167 $\Gamma(a) = \left(a, \gamma \frac{\rho(aR_0 - 1) - v}{(\rho + \gamma)aR_0} \right)^\top$. The endpoints of the curve are
 1168 $\left(1, \gamma \frac{\rho(R_0 - 1) - v}{(\rho + \gamma)R_0} \right)^\top$ and $(0, -\infty)^\top$, so as $a \rightarrow 0$ the curve leaves
 1169 $[0, 1]^2$ and hits the boundary when $a = R_0^{-1}(v/\rho + 1)$. Thus,

1170 the interval of a -values for which the curve is in Ω is $a \in$
 1171 $[R_0^{-1}(v/\rho + 1), 1]$. Note that if $\rho(R_0 - 1) < v$ then the left hand
 1172 endpoint is greater than 1, so the curve never enters $[0, 1]^2$ and
 1173 there are no new normal equilibria. Otherwise, at the left endpoint,
 1174 we have $s = \frac{\rho}{v + \rho}$ and $i = 0$, so we have $\dot{a} = F(R_0^{-1}(v/\rho + 1), 0) > 0$
 1175 by Resilience. At the other endpoint, we have the baseline endemic
 1176 equilibrium with $a = 1$ and $i = \frac{\rho(R_0 - 1) - v}{(\rho + \gamma)R_0}$ and $\dot{a} = F(a, \gamma i) = 0$.
 1177 Moreover,

$$1178 \quad \frac{d}{da} F \circ \Gamma(a) = \frac{d}{da} F \left(a, \gamma \frac{\rho(aR_0 - 1) - v}{(\rho + \gamma)aR_0} \right)$$

$$1179 \quad = F_a(a, \gamma i) + F_c(a, \gamma i) \gamma \frac{di}{da}$$

1180 and, since F is bounded, at the baseline equilibrium we have,

$$1181 \quad \frac{d}{da} F \circ \Gamma(1) = F_a(1, \gamma i)$$

1182 since $F_c(1, \gamma i) = 0$ as shown in Theorem 4. Recall from Theorem
 1183 4 that the baseline equilibrium is stable when $F_a(1, \gamma i) < 0$ and
 1184 unstable when $F_a(1, \gamma i) > 0$. Thus, when the baseline equilibrium
 1185 is unstable, we have $F_a(1, \gamma i) > 0$, so $\frac{d}{da} F \circ \Gamma(1) > 0$, so for all
 1186 $\hat{a} < 1$ sufficiently close to 1 we will have $F \circ \Gamma(\hat{a}) < 0$. Now by
 1187 the intermediate value theorem, there must be an a^* between
 1188 $R_0^{-1}(v/\rho + 1)$ and \hat{a} such that $F \circ \Gamma(a^*) = 0$ and this is a new
 1189 normal equilibrium. \square

1190 **S.2. Analysis of Examples.** In this section we show how to apply the
 1191 Theorems above to analyze reactivity functions using the examples
 1192 from Section 2.

1193 Example 1: Linear Response

1194 The first reactivity function we consider is the linear model
 1195 Eq. (2) given by

$$1196 \quad F_{\text{linear}}(a, c) = w_0 - w_1 a - w_2 c$$

1197 note that $0 = F(1, 0) = w_0 - w_1$, so $w_0 = w_1$ and we can rewrite
 1198 this model as,

$$1199 \quad F_{\text{linear}}(a, c) = w_1(1 - a) - w_2 c$$

1200 where $w_1, w_2 > 0$ so that when $a < 1$ we have $F_{\text{linear}}(a, 0) = w_1(1 -$
 1201 $a) > 0$ so F_{linear} satisfies resilience, and $F_{\text{linear}}(1, c) = -w_2 c \leq 0$
 1202 so F_{linear} satisfies boundedness. At any endemic equilibrium we
 1203 have $aBs = \gamma$ so the incidence is give by

$$1204 \quad c = aBsi = \gamma i = \gamma \left(\frac{(aR_0 - 1)\rho - v}{aR_0(\gamma + \rho)} \right)$$

1205 where we used an alternate form of Eq. (13) for i at equilibrium.
 1206 Substituting this into F_{linear} and setting equal to zero to find the
 1207 equilibrium we have,

$$1208 \quad 0 = w_1(1 - a) - w_2 \left(\gamma \left(\frac{(aR_0 - 1)\rho - v}{aR_0(\gamma + \rho)} \right) \right)$$

1209 so

$$1210 \quad v = (aR_0 - 1)\rho - (a - a^2) \frac{w_1}{w_2} R_0(\rho/\gamma + 1)$$

1211 Notice that for F_{linear} there is a quadratic relationship between
 1212 vaccination and activity at equilibrium, as illustrated in Fig. 3a.
 1213 However, F_{linear} does not necessarily have a baseline endemic
 1214 equilibrium since setting $F_{\text{linear}}(1, c) = -w_2 c = 0$ implies the only
 1215 solution is $c = 0$, which is the disease-free equilibrium. Note that
 1216 if we set $w_2 = 0$ then every c solves $F_{\text{linear}}(1, c) = 0$ so there are
 1217 many baseline endemic equilibria, and the stability condition is
 1218 $F_a(1, \gamma i) = -w_1$

1219 Example 2: Quadratic Response

1220 The second reactivity function we consider is the quadratic
 1221 model Eq. (3), given by

$$1222 \quad F_{\text{quadratic}}(a, c) = (1 - a)(w_1 - w_2 c)$$

1223 where $w_1, w_2 > 0$. If we substitute $c = aBs$ we see that this
 1224 model is quadratic in activity, a . Notice that when $a < 1$ we have
 1225 $F_{\text{quadratic}}(a, 0) = w_1(1 - a) > 0$ so $F_{\text{quadratic}}$ satisfies resilience,
 1226

1241 and $F_{\text{quadratic}}(1, c) = 0 \leq 0$ so $F_{\text{quadratic}}$ satisfies boundedness.
 1242 At any endemic equilibrium we have $aBs = \gamma$ so the incidence is
 1243 give by

$$1244 \quad c = aBsi = \gamma i = \gamma \left(\frac{(aR_0 - 1)\rho - v}{aR_0(\gamma + \rho)} \right)$$

1245 where we used an alternate form of Eq. (13) for i at equilibrium.
 1246 Substituting this into $F_{\text{quadratic}}$ and setting equal to zero to find
 1247 the equilibrium we have,

$$1248 \quad 0 = (1 - a) \left(w_1 - w_2 \gamma \left(\frac{(aR_0 - 1)\rho - v}{aR_0(\gamma + \rho)} \right) \right)$$

1250 so either $a = 1$ (the baseline activity) or we have a new normal
 1251 endemic equilibrium at

$$1252 \quad v = (aR_0 - 1)\rho - aR_0(\rho/\gamma + 1) \frac{w_1}{w_2}.$$

1253 Notice that for $F_{\text{quadratic}}$ there is a linear relationship between
 1254 vaccination and activity as illustrated in Fig. 3a. To solve for the
 1255 second vaccination threshold, T_2 , we set, $F_a(1, \gamma i) = 0$, and solve
 1256 for the vaccination rate, v . For $F_{\text{quadratic}}$ we have,

$$1257 \quad \frac{\partial}{\partial a} F_{\text{quadratic}}(a, c) = w_2 c - w_1$$

1258 so that $\frac{\partial}{\partial a} F_{\text{quadratic}} = 0$ implies

$$1259 \quad \frac{w_1}{w_2} = c = \gamma i = \gamma \left(\frac{(R_0 - 1)\rho - v}{R_0(\gamma + \rho)} \right)$$

1260 and solving for v gives the second vaccination threshold,

$$1261 \quad T_2 = \rho(R_0 - 1) - \frac{w_1}{w_2} R_0(\rho/\gamma + 1)$$

1262 Example 3: Bilinear Response

1263 The third reactivity function we consider is the bilinear function
 1264 Eq. (4), given by

$$1265 \quad F_{\text{bilinear}}(a, c) = (1 - a)(w_1 - w_2 c/a)$$

1266 where $w_1 > 0$ and $w_2 > 0$. It is easy to see that F_{bilinear} satisfies
 1267 resilience and boundedness. If we rewrite this model in terms of
 1268 activity and infection rate we have,

$$1269 \quad F_{\text{bilinear}}(a, aBsi) = (1 - a)(w_1 - w_2 Bsi)$$

1270 so that this model is bilinear in activity and infection rate (rather
 1271 than incidence). To solve for the equilibrium, we compute,

$$1272 \quad 0 = F_{\text{bilinear}}(a, \gamma i) = (1 - a) \left(w_1 - w_2 \gamma \left(\frac{(aR_0 - 1)\rho - v}{a^2 R_0(\gamma + \rho)} \right) \right)$$

1273 so we have an baseline solution, $a = 1$, and a new normal solution,

$$1274 \quad v = (aR_0 - 1)\rho - a^2 R_0(\rho/\gamma + 1) \frac{w_1}{w_2}.$$

1275 To find the second vaccination threshold we set


$$1276 \quad 0 = F_a(1, i\gamma) = w_2 \gamma i - w_1 = w_2 \gamma \left(\frac{(R_0 - 1)\rho - v}{R_0(\gamma + \rho)} \right) - w_1$$

1277 and solve for v to find,

$$1278 \quad T_2 = \rho(R_0 - 1) - \frac{w_1}{w_2} R_0(\rho/\gamma + 1)$$

1279 The connection of $\frac{w_1}{w_2}$ with the threshold T_2 suggests that this
 1280 ratio (and its reciprocal $\frac{w_2}{w_1}$) determine the strength of the response.
 1281 In Fig. S.2 we show that when $\frac{w_2}{w_1}$ is small (top row, yellow
 1282 curves) the behavioral response is weak and dynamics approaches
 1283 that of a classical SIRS model. Moreover, when $\frac{w_2}{w_1}$ is large,
 1284 the behavioral response is more robust and can even lead to an
 1285 increasing series of waves. We should note while the bilinear
 1286 response can create an arbitrarily long series waves with almost
 1287 equal peaks (as shown in the next section) this particular response
 1288 function requires $v > 0$ to obtain increasing waves. It may be
 1289 worth considering that a small $v > 0$ could be used to model a
 1290 subset of the population that become infected and recover without
 1291 ever becoming *infectious*, and thus never entering the i class.

1300 Such a small percentage of cases could potentially arise from very
 1301 mild infections or through extremely rigid isolation that removes
 1302 the possibility of infecting others entirely. Of course, if one is
 1303 interested in capturing the increasing waves observed in Fig. 1,
 1304 one could also consider other response functions and we have
 1305 empirically observed increasing waves without vaccination using
 1306 more complicated response functions.



1307 **Fig. S.2.** Top: Time series of infectious population size with various levels of
 1308 avoidance strength (w_2/w_1) colored in a gradient from weak (yellow) to strong
 1309 (purple). Infectious population size is shown in terms of percentage of population
 1310 (left) and in terms of percentage of the peak infections over the time window (right),
 1311 mirroring Fig. 1 from the manuscript. Bottom: In the bilinear response, peak
 1312 infections decay quickly with increasing avoidance strength (left), while the height
 1313 of the second increases as a percentage of the first peak height until it eventually
 1314 exceeds the first peak (right) which is not observed in the classical SIRS model.

1315 **S.3. Connection to Predator-Prey Models.** If we combine the reac-
 1316 tivity function F_{bilinear} from Eq. (4) with the framework Eq. (12)
 1317 we have the example model,

$$1318 \quad \begin{aligned} \dot{s} &= -aBsi + \rho(1 - s - i) - vs \\ \dot{i} &= aBsi - \gamma i \\ \dot{a} &= (1 - a)(w_1 - w_2 Bsi). \end{aligned} \quad [17]$$

1319 In order to understand the early epidemic dynamics of this model,
 1320 consider $s \approx 1$ as approximately constant and set $d = 1 - a$ so that
 1321 Eq. (17) can be approximately reduced to,


$$1322 \quad \begin{aligned} \dot{i} &= ((Bs - \gamma) - Bsd)i \\ \dot{d} &= (w_2 Bsi - w_1)d. \end{aligned} \quad [18]$$

1323 which is exactly the Lotka-Volterra predator-prey model. Perhaps
 1324 counter-intuitively, in this analogy the infections play the role of
 1325 prey and ‘distancing’, d , plays the role of the predator.

1326 Regardless of the analogy, the interesting feature of this model
 1327 is that it produces oscillations with frequency $\sqrt{w_1 \gamma (R_0 s - 1)}$.
 1328 This approximation is valid when these activity driven oscillations
 1329 are fast enough that s is approximately constant over the course
 1330 of an oscillation. Each oscillation reduces s slightly, and over time
 1331 the frequency decreases. Eventually, when $s < R_0^{-1}$, we have
 1332 $R_0 s - 1 < 0$ which changes the stability of the equilibrium inside
 1333 the periodic orbit of Eq. (18) from a center to a source. Thus,
 1334 $s = R_0^{-1}$ represents a phase transition threshold for this model.

1335 In Fig. 4 we illustrate the range of dynamics that this simple
 1336 reactivity function can exhibit. In this example the infectiousness
 1337 period is 6 days, loss of immunity is 300 days, the infectiousness
 1338 parameter is $B = 0.5$, the reactivity function parameters are
 1339 $w_1 = 0.01$ and $w_2 = 100$. In the high vaccination case (Fig. 4a),
 1340 the system passes through the phase transition quickly and the
 1341 dynamics resemble a classical epidemic. Similarly, when the

1365 vaccination rate is moderate (Fig. 4b) the system quickly relaxes
1366 to the baseline endemic equilibrium. In the low vaccination case
1367 (Fig. 4c) the oscillations continue for an extremely long time (in
1368 fact they are very slowly decreasing in amplitude but would still
1369 be visible after 100 years). In Fig. S.3 we show that by increasing
1370 the reactivity to $w_1 = 0.035$, the high and moderate vaccination
1371 dynamics can initially exhibit predator-prey type oscillations until
1372 the susceptible population is reduced to the phase transition level,
1373 $1/R_0$, at which point the oscillations become classically damped.



1382 **Fig. S.3. Increased reactivity leads to oscillations even with high**
1383 **and moderate vaccination.** Repeating the simulations from the top row of
1384 Fig. 4 but increasing the value of the w_1 parameter to $w_1 = 0.035$.

1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426

1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488